<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00770679</url>
  </required_header>
  <id_info>
    <org_study_id>NA00002253</org_study_id>
    <nct_id>NCT00770679</nct_id>
  </id_info>
  <brief_title>Effects of Statins on Lower Extremity Arterial Function Assessed by Magnetic Resonance Imaging</brief_title>
  <official_title>Effects of Statins on Lower Extremity Arterial Function Assessed by Magnetic Resonance Imaging</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cholesterol-lowering drugs called statins improve the functioning of the endothelium, and
      help prevent heart disease. The investigators are testing whether statins improve endothelial
      function more in the arteries that have worse endothelium to begin with. One of the functions
      of the endothelium is to help control how blood vessels dilate (expand) or contract (narrow)
      in different situations. This affects how blood flows through those vessels. Magnetic
      resonance imaging (MRI) can be used to evaluate endothelial function in the arms and legs
      noninvasively.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Correct
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Delayed recruitment, funding exhausted
  </why_stopped>
  <start_date type="Actual">June 2008</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Change in Low Density Lipoprotein (LDL)</measure>
    <time_frame>Change from baseline to follow-up, up to 5 weeks</time_frame>
    <description>Serum LDL, mg/dL (baseline LDL-follow-up LDL)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Endothelial Function as Measured on MRI in the Arms</measure>
    <time_frame>chance from baseline to end of study, up to 5 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Endothelial Function as Measured on MRI in the Legs</measure>
    <time_frame>chance from baseline to end of study, up to 5 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Diabetes</condition>
  <arm_group>
    <arm_group_label>High-Dose Statin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>80 mg atorvastatin daily for 3 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lipitor</intervention_name>
    <description>80 mg everyday (QD) for 3 weeks</description>
    <arm_group_label>High-Dose Statin</arm_group_label>
    <other_name>atorvastatin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 40-90

          -  Male or female

          -  Type 2 diabetes

        Exclusion Criteria:

          -  Known pregnancy or nursing.

          -  Females of child bearing potential must have been surgically sterilized or be post
             menopausal.

          -  Smoking

          -  Known vascular disease

          -  Inability to complete MRI scan

          -  Symptoms of claudication

          -  Use of a nitrate medicine

          -  Use of any cholesterol-lowering agent

          -  LDL &lt; 70

          -  Acute illness

          -  Liver disease

          -  Contraindication to getting an MRI scan (i.e. electronic implant, shrapnel, cerebral
             aneurysm clip, welding history).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Harry Silber, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>JHU</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Harry SIlber, MD</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 9, 2008</study_first_submitted>
  <study_first_submitted_qc>October 9, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 10, 2008</study_first_posted>
  <results_first_submitted>July 17, 2017</results_first_submitted>
  <results_first_submitted_qc>August 14, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">September 13, 2017</results_first_posted>
  <last_update_submitted>August 14, 2017</last_update_submitted>
  <last_update_submitted_qc>August 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
    <mesh_term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>High-Dose Statin</title>
          <description>80 mg atorvastatin daily for 3 weeks
lipitor: 80 mg everyday (QD) for 3 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Follow-up LDL measurement not collected</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>High-Dose Statin</title>
          <description>80 mg atorvastatin daily for 3 weeks
lipitor: 80 mg everyday (QD) for 3 weeks</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>&gt;=40, &lt;=90, years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Change in Low Density Lipoprotein (LDL)</title>
        <description>Serum LDL, mg/dL (baseline LDL-follow-up LDL)</description>
        <time_frame>Change from baseline to follow-up, up to 5 weeks</time_frame>
        <population>3 participants were lost to follow-up, 3 participants did not have LDL values collected/reported at follow-up</population>
        <group_list>
          <group group_id="O1">
            <title>High-Dose Statin</title>
            <description>80 mg atorvastatin daily for 3 weeks
lipitor: 80 mg everyday (QD) for 3 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Low Density Lipoprotein (LDL)</title>
          <description>Serum LDL, mg/dL (baseline LDL-follow-up LDL)</description>
          <population>3 participants were lost to follow-up, 3 participants did not have LDL values collected/reported at follow-up</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.54" spread="12.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Endothelial Function as Measured on MRI in the Arms</title>
        <time_frame>chance from baseline to end of study, up to 5 weeks</time_frame>
        <population>No data was collected for this outcome measure. The outcome was not able to be calculated based upon data obtained and programs and investigator capabilities.</population>
        <group_list>
          <group group_id="O1">
            <title>High-Dose Statin</title>
            <description>80 mg atorvastatin daily for 3 weeks
lipitor: 80 mg everyday (QD) for 3 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Endothelial Function as Measured on MRI in the Arms</title>
          <population>No data was collected for this outcome measure. The outcome was not able to be calculated based upon data obtained and programs and investigator capabilities.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Endothelial Function as Measured on MRI in the Legs</title>
        <time_frame>chance from baseline to end of study, up to 5 weeks</time_frame>
        <population>No data was collected for this outcome measure. The outcome was not able to be calculated based upon data obtained and programs and investigator capabilities.</population>
        <group_list>
          <group group_id="O1">
            <title>High-Dose Statin</title>
            <description>80 mg atorvastatin daily for 3 weeks
lipitor: 80 mg everyday (QD) for 3 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Endothelial Function as Measured on MRI in the Legs</title>
          <population>No data was collected for this outcome measure. The outcome was not able to be calculated based upon data obtained and programs and investigator capabilities.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>High-Dose Statin</title>
          <description>80 mg atorvastatin daily for 3 weeks
lipitor: 80 mg everyday (QD) for 3 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Harry Silber, M.D., Ph.D. Assistant Professor of Medicine, Division of Cardiology</name_or_title>
      <organization>Johns Hopkins University School of Medicine</organization>
      <phone>4105505717</phone>
      <email>hsilber@jhmi.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

